Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre
- 1Karolinska Institutet
Abstract
PurposeThe Karolinska Liver Metastases (KaroLiver) cohort was established to investigate associations between clinical characteristics and histopathological features in patients treated with curative intent for colorectal cancer liver metastases (CRLM). The cohort combines whole-slide digital histopathology images with detailed oncological, surgical, radiological and survival data, enabling comprehensive analyses of treatment trajectories, clinical outcomes and metastatic tumour biology.
ParticipantsKaroLiver is a retrospective observational cohort comprising all consecutive patients who received curative-intent, liver-directed treatment for CRLM at Karolinska University Hospital in Stockholm, Sweden. The hospital is the primary regional referral centre for HPB surgery, serving the population of approximately 2.5 million people in the Stockholm-Gotland healthcare region. Patient enrolment is continuously updated in accordance with amended ethical approvals and evolving scientific questions. The cohort currently comprises 811 patients who underwent 1204 liver interventions between February 2012 and January 2022. Detailed clinical, oncological, surgical, pathological, molecular, recurrence and survival data are collected.
Findings to dateMedian overall survival (OS) in the current cohort is 51.0 months (95% CI 46.2-57.1 months), and median recurrence-free survival (RFS) is 10.4 months (95% CI 9.2-11.9 months). The five-year OS rate is 44.9% (95% CI 41.2-48.8%). Studies using the cohort have so far identified a liver injury-derived stromal capsule in a subset of metastases, associated with improved survival. The cohort has also enabled the identification of histopathological markers of tumour biology, sex-based differences in treatment and survival, and associations between post-hepatectomy liver failure and oncological outcomes.
Future plansCurrent research priorities include advanced histology-based prognostic scoring, sex differences in recurrence and retreatment, tumour biology and outcomes in early-onset versus average-onset CRLM, as well as CT- and MRI-based radiomics, all integrated within KaroLivers histopathological framework. Data sharing is supported, given that regulatory requirements are met. Retrospective accrual and outcome updates will continue for current and future studies, subject to the required approvals.
Strengths and limitations of this study{square} Selection bias in KaroLiver is minimised through consecutive, population-based accrual of all patients receiving curative-intent liver-directed treatment for CRLM at a high-volume Swedish tertiary centre. {square}Granular data on recurrence, including site, timing, and intent of retreatment, enable detailed analyses of disease trajectories beyond the index hepatectomy. {square}KaroLiver is linked to CT and MRI examinations from diagnosis through recurrence; combined with detailed histopathological and molecular pathology data, this provides a platform for translational research, based on specific, defined research questions. {square}The observational design limits causal inference, and changes in treatment strategies and follow-up protocols over the study period may introduce temporal confounding that must be accounted for in analyses. {square}Molecular data, including RAS/RAF mutation status and mismatch repair status, are incomplete, reflecting real-world clinical practice and the gradual adoption of tumour profiling over the study period.
Related
- Application of relative elastic modulus in patients with liver metastases from colorectal cancer receiving first-line treatment
- A Contemporary Review of Resectability and Treatment Strategies for Colorectal Liver Metastases: Part 2-Advanced Surgical Techniques, Conversion Strategies, and the Expanding Boundaries of Treatment.
- MRI-based intratumoral and peritumoral heterogeneity for predicting intracranial progression in EGFR-mutant lung adenocarcinoma patients with treatment-naive brain metastases receiving first-line third-generation EGFR-TKIs.
- Rethinking Surgical Margins in Colorectal Liver Metastases: Vessel-Skeletonized Parenchymal-Sparing Hepatectomy (VESPAH) and Treatment Continuity
- A Contemporary Review of Resectability and Treatment Strategies for Colorectal Liver Metastases: Part 1—Diagnosis, Defining Resectability, and Management of Upfront Resectable and Synchronous Disease
BibTeX
@misc{gerling2026cohort,
title = {{Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre}},
author = {M. Gerling and C. F. Moro and C. Limbecker and A. Viljamaa and S. Harrizi and Y. Hamidi and A.-K. Hailer and J. Sterner and E. Sparrelid and L. Bozoky and E. Tidholm Qvist and R. Baumgartner and M. Salmonson Schaad and B. Bozoky and N. Geyer and J. Engstrand},
howpublished = {medRxiv},
year = {2026},
month = aug,
doi = {10.64898/2026.08.24.26361235},
url = {https://www.medrxiv.org/content/10.64898/2026.08.24.26361235v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre
AU - M. Gerling
AU - C. F. Moro
AU - C. Limbecker
AU - A. Viljamaa
AU - S. Harrizi
AU - Y. Hamidi
AU - A.-K. Hailer
AU - J. Sterner
AU - E. Sparrelid
AU - L. Bozoky
AU - E. Tidholm Qvist
AU - R. Baumgartner
AU - M. Salmonson Schaad
AU - B. Bozoky
AU - N. Geyer
AU - J. Engstrand
PY - 2026
DA - 2026/08/24
PB - medRxiv
DO - 10.64898/2026.08.24.26361235
UR - https://www.medrxiv.org/content/10.64898/2026.08.24.26361235v1
AB - PurposeThe Karolinska Liver Metastases (KaroLiver) cohort was established to investigate associations between clinical characteristics and histopathological features in patients treated with curative intent for colorectal cancer liver metastases (CRLM). The cohort combines whole-slide digital histopathology images with detailed oncological, surgical, radiological and survival data, enabling comprehensive analyses of treatment trajectories, clinical outcomes and metastatic tumour biology. ParticipantsKaroLiver is a retrospective observational cohort comprising all consecutive patients who received curative-intent, liver-directed treatment for CRLM at Karolinska University Hospital in Stockholm, Sweden. The hospital is the primary regional referral centre for HPB surgery, serving the population of approximately 2.5 million people in the Stockholm-Gotland healthcare region. Patient enrolment is continuously updated in accordance with amended ethical approvals and evolving scientific questions. The cohort currently comprises 811 patients who underwent 1204 liver interventions between February 2012 and January 2022. Detailed clinical, oncological, surgical, pathological, molecular, recurrence and survival data are collected. Findings to dateMedian overall survival (OS) in the current cohort is 51.0 months (95% CI 46.2-57.1 months), and median recurrence-free survival (RFS) is 10.4 months (95% CI 9.2-11.9 months). The five-year OS rate is 44.9% (95% CI 41.2-48.8%). Studies using the cohort have so far identified a liver injury-derived stromal capsule in a subset of metastases, associated with improved survival. The cohort has also enabled the identification of histopathological markers of tumour biology, sex-based differences in treatment and survival, and associations between post-hepatectomy liver failure and oncological outcomes. Future plansCurrent research priorities include advanced histology-based prognostic scoring, sex differences in recurrence and retreatment, tumour biology and outcomes in early-onset versus average-onset CRLM, as well as CT- and MRI-based radiomics, all integrated within KaroLivers histopathological framework. Data sharing is supported, given that regulatory requirements are met. Retrospective accrual and outcome updates will continue for current and future studies, subject to the required approvals. Strengths and limitations of this study{square} Selection bias in KaroLiver is minimised through consecutive, population-based accrual of all patients receiving curative-intent liver-directed treatment for CRLM at a high-volume Swedish tertiary centre. {square}Granular data on recurrence, including site, timing, and intent of retreatment, enable detailed analyses of disease trajectories beyond the index hepatectomy. {square}KaroLiver is linked to CT and MRI examinations from diagnosis through recurrence; combined with detailed histopathological and molecular pathology data, this provides a platform for translational research, based on specific, defined research questions. {square}The observational design limits causal inference, and changes in treatment strategies and follow-up protocols over the study period may introduce temporal confounding that must be accounted for in analyses. {square}Molecular data, including RAS/RAF mutation status and mismatch repair status, are incomplete, reflecting real-world clinical practice and the gradual adoption of tumour profiling over the study period.
ER -